My CGPT chat might be of interest...29 Jan 2026 10:43
You’ve framed the exact right decision tree for Scancell 👍
At this stage it’s no longer “is the science real?” — it’s who funds Phase 3, on what terms, and when.
Let’s walk this cleanly from worst → base → best case, and translate each into valuation logic, not hype.
🔬 Scancell (SCLP) — Scenario Framework
Current position
Market cap: ~£140m
Lead asset: iSCIB1+ melanoma (Phase 3–ready, FDA IND cleared)
Cash runway: into H2 2026
Phase 3 not funded
Clear regulatory path, strong Phase 2 data
This is now a financing / deal-structure company, not a science-risk company.
🟥 WORST CASE
“No partner, funding pressure, valuation compression”
What happens
No meaningful partnership announced in next 6–9 months
Cash visibly running down
Pharma waits strategically
Market starts pricing distress optionality
This is extremely common in UK biotech.
Likely company actions
Bridging raise
Deeply discounted equity
Possibly with warrants
Or structured financing (convertible)
Market psychology
“Why partner now when you can buy later?”
“Why pay £300m EV when you can wait for £80–100m?”
This is the classic AIM trap.
Valuation impact
In this scenario, the market stops valuing rNPV and starts valuing cash + bargaining position.
You’d likely see:
Metric Outcome
Enterprise value £60–90m
Market cap £70–100m
Share price –30% to –50% from here
Even with good science.
📉 This is the asymmetric downside you’re correctly worried about.
Key insight:
Science success ≠ shareholder success if funding leverage is weak.
🟧 BASE CASE
“Partner discussions continue, nothing signed yet”
This is actually the most probable scenario.
What happens
Ongoing partnering talks
Positive language
No formal deal yet
Phase 3 planning progresses
Market oscillates with sentiment
What the market does
Applies a financing discount
Prices partial success
Keeps valuation capped
Typical AIM behavior:
Investors “wait for confirmation”
Stock drifts or ranges
Likely valuation range
Scenario Market cap
Ongoing talks £120–180m
Share price Flat to +25%
rNPV discount ~40–50%
This is roughly where the stock is now.
📊 The market is currently saying:
“Yes, this looks real — but show us who’s paying.”
🟩 BEST CASE
“Phase 3 funded via partner or acquisition”
This is where things change structurally.
There are two different best cases, and they have very different outcomes.
🟩 Best Case A — Phase 3 Partnered
Example structure
Pharma funds Phase 3
Scancell retains royalties (10–20%)
Possible upfront payment (£20–50m)
Milestones on approval
This is hugely value-accretive.
Why?
Because it removes the biggest rNPV haircut:
❌ funding risk
❌ dilution risk
❌ execution uncertainty
Suddenly your discount rate drops mat
Sign In
Follow the stocks
